In late May, the National Comprehensive Cancer Network (NCCN) announced updates to two NCCN Clinical Practice Guidelines in Oncology(TM) -- Esophageal Cancer and Gastric Cancer. The panel added oral fluoropyrimidine, Capecitabine (Xeloda(R), Roche) as an option for treatment of esophageal and gastric cancer due to favorable Phase III trials. The panel also states that capecitabine may replace 5-FU and oxaliplatin may replace cisplatin in triplet regimens for advanced esophageal and gastric cancer.
Additional updates and the NCCN Clinical Practice Guidelines in Oncology(TM) are available at www.nccn.org free of charge.
